Ginwa Enterprise (Group) Inc (600080) Fair Value & Analysis
Healthcare · CN · Market cap 1.8B CNY
Fair value as of: Jun 24, 2026
Analysis
Ginwa Enterprise (Group) Inc (600080) currently trades at ¥4.54, while our model-based Fair Value estimate is ¥1.00 — implying the stock looks roughly 78.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is headquartered in Xi'an, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Ginwa Enterprise (Group) Inc (600080) undervalued?
What is the fair value of 600080?
What is the quality score of 600080?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.